Day: June 13, 2021

FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced that the Company will host a conference call and live webcast on Monday, June 14, 2021 at 8:30 a.m. ET (5:30 a.m. PT) to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with NASH. Webcast and conference call details are as follows: Webcast link: https://edge.media-server.com/mmc/p/2gsxxmta Live Conference CallDomestic Callers (U.S./Canada toll-free): (833) 665-0612International Callers: (929) 517-0403Conference ID: 7587739 Following the...

VANCOUVER, British Columbia, June 13, 2021 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning”, “the Company”, “we”, “our” or “us”) is hosting a virtual Investor Day on June 14 starting at 11:00 AM Eastern Time. Following the presentations by members of our leadership team, participants will have an opportunity to ask questions using the webcast portal. “We continue to execute on our Global Strategic Priorities designed to improve our return on invested capital performance and ultimately increase our earnings capacity. Robust execution through 2020 put us back on track to achieve strong ROIC in line with our 2018 investor day objectives, albeit one year later. Significant ROIC improvements in all three regions will be increasingly evident starting with our Q2 2021 results, as improved market activity that we had...

SOUTH SAN FRANCISCO, Calif., June 13, 2021 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that the Company plans to report top line data from its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis (AD) in a premarket press release and webcast on Monday, June 14, 2021. RAPT will host a conference call accompanied by a slide presentation at 8:30 a.m. ET on Monday, June 14th. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. The call can...